CA3067696C - 18f-labelled compound for prostate cancer diagnosis, and use thereof - Google Patents

18f-labelled compound for prostate cancer diagnosis, and use thereof Download PDF

Info

Publication number
CA3067696C
CA3067696C CA3067696A CA3067696A CA3067696C CA 3067696 C CA3067696 C CA 3067696C CA 3067696 A CA3067696 A CA 3067696A CA 3067696 A CA3067696 A CA 3067696A CA 3067696 C CA3067696 C CA 3067696C
Authority
CA
Canada
Prior art keywords
compound
added
dissolved
prostate cancer
minutes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3067696A
Other languages
English (en)
French (fr)
Other versions
CA3067696A1 (en
Inventor
Dae Yoon Chi
Byoung Se Lee
So Young Chu
Woon Jung Jung
Hyeon Jin Jeong
Min Hwan Kim
Mi Hyun Kim
Kyo Chul Lee
Yong Jin Lee
Ji Ae Park
Ran Ji Yoo
Sang Moo Lim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Futurechem Co Ltd
Original Assignee
Futurechem Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Futurechem Co Ltd filed Critical Futurechem Co Ltd
Priority claimed from PCT/KR2018/006869 external-priority patent/WO2018236115A1/ko
Publication of CA3067696A1 publication Critical patent/CA3067696A1/en
Application granted granted Critical
Publication of CA3067696C publication Critical patent/CA3067696C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/04—1,2,3-Triazoles; Hydrogenated 1,2,3-triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Radiology & Medical Imaging (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nuclear Medicine (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CA3067696A 2017-06-19 2018-06-18 18f-labelled compound for prostate cancer diagnosis, and use thereof Active CA3067696C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2017-0077570 2017-06-19
KR20170077570 2017-06-19
KR1020180069590A KR102015355B1 (ko) 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도
KR10-2018-0069590 2018-06-18
PCT/KR2018/006869 WO2018236115A1 (ko) 2017-06-19 2018-06-18 전립선암 진단을 위한 18f-표지된 화합물 및 그의 용도

Publications (2)

Publication Number Publication Date
CA3067696A1 CA3067696A1 (en) 2018-12-27
CA3067696C true CA3067696C (en) 2022-05-03

Family

ID=65008286

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3067696A Active CA3067696C (en) 2017-06-19 2018-06-18 18f-labelled compound for prostate cancer diagnosis, and use thereof

Country Status (21)

Country Link
US (1) US10870629B2 (https=)
EP (1) EP3643707B1 (https=)
JP (1) JP6913968B2 (https=)
KR (1) KR102015355B1 (https=)
CN (1) CN110770212B (https=)
AU (1) AU2018288907B2 (https=)
CA (1) CA3067696C (https=)
CL (1) CL2019003727A1 (https=)
DK (1) DK3643707T3 (https=)
EA (1) EA037781B1 (https=)
ES (1) ES2912392T3 (https=)
HR (1) HRP20220557T1 (https=)
LT (1) LT3643707T (https=)
MX (1) MX388833B (https=)
MY (1) MY195426A (https=)
PH (1) PH12019502665A1 (https=)
PL (1) PL3643707T3 (https=)
PT (1) PT3643707T (https=)
RS (1) RS63205B1 (https=)
SG (1) SG11201911602RA (https=)
SI (1) SI3643707T1 (https=)

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2494096C2 (ru) 2008-08-01 2013-09-27 Дзе Джонс Хопкинс Юниверсити Агенты, связывающиеся с psma, и их применение
WO2013022797A1 (en) * 2011-08-05 2013-02-14 Molecular Insight Pharmaceuticals Radiolabeled prostate specific membrane antigen inhibitors
WO2013028664A1 (en) 2011-08-22 2013-02-28 Siemens Medical Solutions Usa, Inc. Psma imaging agents
JP2014051442A (ja) * 2012-09-05 2014-03-20 Kyoto Univ 前立腺がんを診断可能な核医学イメージングプローブ
EP3300746B1 (en) * 2013-01-14 2019-05-15 Molecular Insight Pharmaceuticals, Inc. Triazine based radiopharmaceuticals and radioimaging agents
ES3005832T3 (en) 2013-11-13 2025-03-17 Ge Healthcare Ltd Dual run cassette for the synthesis of 18f-labelled compounds
KR20150113801A (ko) * 2014-03-31 2015-10-08 한미약품 주식회사 Tak1 저해 활성을 갖는 피라진 접합고리 유도체
FR3023290B1 (fr) * 2014-07-04 2016-08-19 Pf Medicament Derives de flavaglines
WO2017027870A1 (en) * 2015-08-13 2017-02-16 The Johns Hopkins University Triazole conjugated ureas, thioureas, carbamates, and "reversed" carbamates for psma-targeted imaging agents and uses thereof
EP3493856B1 (en) 2016-06-28 2023-08-09 Cornell University 18f-labeled triazole containing psma inhibitors

Also Published As

Publication number Publication date
CN110770212B (zh) 2022-11-22
DK3643707T3 (da) 2022-05-09
JP2020524175A (ja) 2020-08-13
EP3643707A4 (en) 2021-06-09
RS63205B1 (sr) 2022-06-30
US10870629B2 (en) 2020-12-22
PT3643707T (pt) 2022-05-04
CA3067696A1 (en) 2018-12-27
EA202090071A1 (ru) 2020-04-16
AU2018288907B2 (en) 2020-05-07
AU2018288907A1 (en) 2020-01-23
SI3643707T1 (sl) 2022-06-30
HRP20220557T1 (hr) 2022-06-10
KR102015355B1 (ko) 2019-10-23
CL2019003727A1 (es) 2020-07-03
EP3643707B1 (en) 2022-02-23
US20200207724A1 (en) 2020-07-02
CN110770212A (zh) 2020-02-07
SG11201911602RA (en) 2020-01-30
KR20180138169A (ko) 2018-12-28
MY195426A (en) 2023-01-20
EA037781B1 (ru) 2021-05-20
MX388833B (es) 2025-03-12
PH12019502665A1 (en) 2020-10-26
ES2912392T3 (es) 2022-05-25
BR112019027183A2 (pt) 2020-06-30
PL3643707T3 (pl) 2023-06-12
EP3643707A1 (en) 2020-04-29
LT3643707T (lt) 2022-05-25
JP6913968B2 (ja) 2021-08-04
MX2019015616A (es) 2020-02-26

Similar Documents

Publication Publication Date Title
AU2020201086B2 (en) Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
KR102233726B1 (ko) 전립선 특이적 막 항원（psma)의 18f-태그된 저해제 및 전립선암에 대한 조영제로서 이의 용도
EP3209336B1 (en) 18f-tagged inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
EP3375787B1 (en) Peptide thiourea derivative, radioisotope labeled compound containing same, and pharmaceutical composition containing same as active ingredient for treating or diagnosing prostate cancer
CN101151054B (zh) 放射性氟化肽
CA2828810A1 (en) Radiolabelled octreotate analogues as pet tracers
CA3205844A1 (en) Ligands and their use
CA3067696C (en) 18f-labelled compound for prostate cancer diagnosis, and use thereof
JP2020524175A5 (https=)
Kim et al. Synthesis and characterization of 64Cu-and Cy5. 5-labeled tetraiodothyroacetic acid derivatives for tumor angiogenesis imaging
JP7834363B2 (ja) トレーサー化合物およびその調製方法
KR101375639B1 (ko) 아미노시클로펜탄카르복실산-함유 시클로 ｒｇｄ 유도체, 그 제조방법 및 그것을 포함하는 ｐｅｔ 조영제
KR20250127541A (ko) 방사성 동위원소가 표지된 할로겐화 벤즈아마이드 유도체 화합물을 유효성분으로 포함하는 암의 진단 또는 치료용 조성물
BR112019027183B1 (pt) Composição farmacêutica para tratar ou diagnosticar câncer de próstata, radiofármaco para diagnóstico por imageamento de câncer de próstata
HK40099290A (zh) 配体及其用途
WO2014049274A1 (fr) Nouveaux composes comportant des groupements dendrimeriques iodes ou fluores, leurs procédés de préparation et leurs utilisations

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20191217

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - STANDARD

Year of fee payment: 7

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250520

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250520